The findings presented in this study illustrate that JPD substantially mitigated the pathological manifestations of MASH, as evidenced by a notable reduction in AST/ALT levels, amelioration of hepatic steatosis, diminished oxidative stress, and decreased inflammatory infiltration. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatohepatitis.